Pfizer forecasts $26B in coronavirus vaccine revenue this year | BioPharma Dive

Even in countries that have vaccinated many of their citizens, like the U.S., U.K. and Israel, there will likely be continued demand for more doses as adolescents and children become eligible. An authorization from the Food and Drug Administration for adolescents aged 12 to 15 years is expected soon, possibly by early next week.  Pfizer, along with other vaccine makers, is also anticipating booster shots will be needed to maintain long-term immunity against coronavirus infection. In a recent interview with CNBC, Bourla said he expects a booster would be needed within a year of full vaccination.

Source: Pfizer forecasts $26B in coronavirus vaccine revenue this year | BioPharma Dive

Source: Pfizer forecasts $26B in coronavirus vaccine revenue this year | BioPharma Dive